Draft National Level Listed Species Biological Evaluation for Propazine

In November 2020, EPA released the draft Biological Evaluation (BE) assessing risks to listed species from labeled uses of propazine. The term "listed species" refers to those that are federally listed as endangered or threatened, as well as experimental populations and species that are proposed and candidates for listing. The draft BE was conducted according to the Revised Method for National Level Listed Species Biological Evaluations of Conventional Pesticides.

The Revised Method described in this document incorporates:

Recommendations from the National Research Council of the National Academy of Sciences (NAS);
EPA’s “lessons learned” during the first three pilot BEs;
Public comments provided through
- stakeholder meetings,
- the docket on the draft BEs for chlorpyrifos, diazinon and malathion, and
- the docket on the proposed Revised Method;
Comments received during consultation with federally recognized tribes; and
Input provided by U.S. Fish and Wildlife Service, National Marine Fisheries Service and the US Department of Agriculture.

The draft BE for propazine is provided below. The models and tools used to conduct this BE can be found here. In January 2021, after the draft BE was completed, the only propazine registrant requested to voluntarily cancel its remaining product registrations. On June 8, 2021, EPA issued a final cancellation order for propazine, which terminated the last propazine products registered in the United States; therefore, EPA did not complete a final BE for this active ingredient.

The draft BE can be found at www.regulations.gov under docket EPA-HQ-OPP-2020-0514.

On this page: